[go: up one dir, main page]

SI1904048T1 - Inhibitorji glepp-1 pri zdravljenju avtoimunskih in/ali vnetnih obolenj - Google Patents

Inhibitorji glepp-1 pri zdravljenju avtoimunskih in/ali vnetnih obolenj

Info

Publication number
SI1904048T1
SI1904048T1 SI200631196T SI200631196T SI1904048T1 SI 1904048 T1 SI1904048 T1 SI 1904048T1 SI 200631196 T SI200631196 T SI 200631196T SI 200631196 T SI200631196 T SI 200631196T SI 1904048 T1 SI1904048 T1 SI 1904048T1
Authority
SI
Slovenia
Prior art keywords
glepp
autoimmune
treatment
inhibitors
inflammatory disorders
Prior art date
Application number
SI200631196T
Other languages
English (en)
Inventor
Agnes Bombrun
Van Huijsduijnen Rob Hooft
Catherine Jorand-Lebrun
Pierre-Alain Vitte
Patrick Gerber
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of SI1904048T1 publication Critical patent/SI1904048T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41521,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI200631196T 2005-07-15 2006-07-14 Inhibitorji glepp-1 pri zdravljenju avtoimunskih in/ali vnetnih obolenj SI1904048T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05106547 2005-07-15
US70636505P 2005-08-08 2005-08-08
EP06777795A EP1904048B1 (en) 2005-07-15 2006-07-14 Glepp-1 inhibitors in the treatment of autoimmune and/or inflammatory disorders
PCT/EP2006/064288 WO2007009959A1 (en) 2005-07-15 2006-07-14 Glepp-1 inhibitors in the treatment of autoimmune and/or inflammatory disorders

Publications (1)

Publication Number Publication Date
SI1904048T1 true SI1904048T1 (sl) 2012-01-31

Family

ID=35423337

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200631196T SI1904048T1 (sl) 2005-07-15 2006-07-14 Inhibitorji glepp-1 pri zdravljenju avtoimunskih in/ali vnetnih obolenj

Country Status (24)

Country Link
US (1) US20080207722A1 (sl)
EP (1) EP1904048B1 (sl)
JP (1) JP2009501197A (sl)
KR (1) KR20080036084A (sl)
CN (1) CN101282719A (sl)
AT (1) ATE534380T1 (sl)
AU (1) AU2006271682B2 (sl)
BR (1) BRPI0613400A2 (sl)
CA (1) CA2609929A1 (sl)
CY (1) CY1112148T1 (sl)
DK (1) DK1904048T3 (sl)
EA (1) EA200800342A1 (sl)
ES (1) ES2377881T3 (sl)
HR (1) HRP20110875T1 (sl)
IL (1) IL188735A (sl)
MX (1) MX2008000665A (sl)
NO (1) NO20080781L (sl)
PL (1) PL1904048T3 (sl)
PT (1) PT1904048E (sl)
RS (1) RS52116B (sl)
SI (1) SI1904048T1 (sl)
UA (1) UA94049C2 (sl)
WO (1) WO2007009959A1 (sl)
ZA (1) ZA200710497B (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02414B (me) * 2009-07-30 2016-09-20 Teva Pharma Tretman kronove bolesti lakvinimodom
US9493436B2 (en) * 2011-04-26 2016-11-15 Indiana University Research And Technology Corporation Tyrosine phosphatase inhibitors and uses thereof to modulate the activity of enzymes involved in the pathology of Mycobacterium tuberculosis
BR112018012825A2 (pt) * 2015-12-22 2018-12-04 Syngenta Participations Ag derivados de oxadiazol microbiocidas
CN107936110B (zh) * 2017-11-07 2021-06-22 潍坊医学院 突变基因Nasp在狼疮性模型小鼠自身免疫病发病中的作用及机制
CN115297860B (zh) * 2020-04-06 2024-10-15 普渡研究基金会 新型n-芳基草氨酸
US20250332138A1 (en) * 2022-01-27 2025-10-30 Vivozon, Inc. Pharmaceutical composition for preventing or treating mental disorder
CN118239851B (zh) * 2024-03-20 2025-07-25 蚌埠医科大学 一种ptpro抑制剂的制备方法及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
DE59509577D1 (de) * 1995-02-16 2001-10-11 Merck Patent Gmbh Vinylenverbindungen und flüssigkristallines Medium
AU5347496A (en) * 1995-04-21 1996-11-07 Daiichi Pharmaceutical Co., Ltd. Ethynylthiazole derivative
FR2762514B1 (fr) * 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
EP1434585A1 (en) * 2001-10-12 2004-07-07 Warner-Lambert Company LLC Alkyne matrix metalloproteinase inhibitors
AU2002342859B2 (en) * 2001-10-30 2007-07-26 Merck Serono Sa Oxindole hydrazide modulators of protein tyrosine phosphatases (PTPS)
JP2003171305A (ja) * 2001-11-30 2003-06-20 Yunie:Kk 糖尿病改善治療剤
JP2005170790A (ja) 2002-01-09 2005-06-30 Ajinomoto Co Inc N−アルキルスルフォニル置換アミド誘導体
EP1470102B1 (en) * 2002-01-29 2011-05-25 Merck Serono SA Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (ptps)
JP2006523196A (ja) 2003-03-11 2006-10-12 ニューロサーチ、アクティーゼルスカブ 新規kcnqチャネルを調節する化合物及びその医薬用途
EP1654247B1 (en) * 2003-07-21 2010-01-20 Merck Serono SA Alkynyl aryl carboxamides
WO2005007616A1 (en) 2003-07-23 2005-01-27 Warner-Lambert Company Llc Diphenylamino ketone derivatives as mek inhibitors
CA2560648C (en) * 2004-04-07 2013-01-22 Applied Research Systems Ars Holding N.V. 1,1'-(1,2-ethynediyl)bis-benzene derivatives as ptp 1-b inhibitors

Also Published As

Publication number Publication date
EP1904048B1 (en) 2011-11-23
ATE534380T1 (de) 2011-12-15
CN101282719A (zh) 2008-10-08
WO2007009959A1 (en) 2007-01-25
MX2008000665A (es) 2008-03-13
ZA200710497B (en) 2009-04-29
CY1112148T1 (el) 2015-11-04
EA200800342A1 (ru) 2008-08-29
IL188735A0 (en) 2008-12-29
CA2609929A1 (en) 2007-01-25
AU2006271682A1 (en) 2007-01-25
IL188735A (en) 2012-07-31
RS52116B (sr) 2012-08-31
NO20080781L (no) 2008-02-13
JP2009501197A (ja) 2009-01-15
KR20080036084A (ko) 2008-04-24
PL1904048T3 (pl) 2012-04-30
US20080207722A1 (en) 2008-08-28
EP1904048A1 (en) 2008-04-02
ES2377881T3 (es) 2012-04-02
DK1904048T3 (da) 2011-12-19
AU2006271682B2 (en) 2012-07-05
UA94049C2 (ru) 2011-04-11
PT1904048E (pt) 2011-12-19
HRP20110875T1 (hr) 2011-12-31
BRPI0613400A2 (pt) 2011-01-11

Similar Documents

Publication Publication Date Title
TN2009000381A1 (en) C5 antigens and uses thereof
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
IL197080A0 (en) Pyrimidone compounds as gsk-3 inhibitors
IL190201A0 (en) Pde inhibitors and combinations thereof for the treatment of urological disorders
MX2010008397A (es) Inhibidores del receptor de quimioquinas cxcr3.
IL219644A0 (en) Kinase inhibitors and methods of use thereof
MX2009004757A (es) Moduladores de regeneracion neuronal.
IL188735A0 (en) Use of glepp-1 inhibitor for the menufacture of a medicament for treament of an autoimmune and/or inflamatory disorder
WO2007084542A3 (en) Treatment of inflammatory disorders with triazole compounds
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
IL193943A0 (en) The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain
ATE489947T1 (de) Axomadol zur schmerzbehandlung bei arthrose
WO2006124477A3 (en) Combination therapy with inhibitors of hmgb and caspase for the treatment of inflammatory diseases
UA96736C2 (ru) Ингибиторы pi3k для лечения эндометриоза
IL193944A0 (en) The use beta-aminoalcohols for the treatment of inflammatory disorders and pain
ATE552888T1 (de) Elastasehemmer bei leukämie
MX2009004296A (es) Inhibidores de canal ih para promover insomnio.
ZA200802668B (en) PDE inhibitors and combinations thereof for the treatment of urological disorders
SG165343A1 (en) Jnk inhibitors for the treatment of endometriosis
TN2010000369A1 (en) Inhibitors of the chemokine receptor cxcr3
UA98926C2 (ru) Ингибитор митотических кинезинов и его использование
HK1120217A (en) The use of beta-aminoalcohols for the treatment of inflammatory disorders and pain